. 2020 Apr 13;12(4):960. doi: 10.3390/cancers12040960

Table 1.

Circulating Tumor Cells (CTCs) in melanoma: clinical studies listed in the ClinicalTrials.gov database.

N°	Status	Study Title	Cancer	Location	Outcomes	Measurements
1	Completed	Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers	Melanoma and other cancers	Comprehensive Cancer Centers of Nevada	Technological validation	CTC culture and analysis
1	Completed		Melanoma and other cancers	Las Vegas, Nevada, United States	Survival evaluation
2	Completed	Study of Circulating Tumor Cells Before and After Treatment in Patients with Metastatic Melanoma	Metastatic Melanoma	CHU of Nice, Nice, France	CTC evaluation from pre- to post-treatment	CTC analysis
2	Completed		Metastatic Melanoma		Survival evaluation	Treatment follow-up
3	Recruiting	Biomarker Analysis Using Circulating Tumor Cells in Patients with Melanoma	Melanoma Stage I-IV	Abramson Cancer Center of the University of Pennsylvania	CTC evaluation during treatment	CTC analysis
3	Recruiting		Melanoma Stage I-IV	Philadelphia, Pennsylvania, United States		Treatment follow-up
4	Completed	Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques	Metastatic Melanoma	CHU of Montpellier, Montpellier, France	Technological validation	CTC analysis
4	Completed		Metastatic Melanoma	CHU of Nîmes, Nîmes, France	Survival evaluation
5	Recruiting	In Vivo Real-time Detection of Circulating Melanoma Cells	Melanoma Stage I-IV	University of Arkansas for Medical Sciences	Technological validation	CTC analysis
5	Recruiting	In Vivo Real-time Detection of Circulating Melanoma Cells	Melanoma Stage I-IV	Little Rock, Arkansas, United States
6	Recruiting	Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology	Melanoma	Saint-Louis Hospital	Therapeutic response	CTC culture and analysis
6	Recruiting		Stage III–IV	Paris, France	Survival evaluation
7	Unknown ^†	Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma	Melanoma Stage III–IV	Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States	Therapy and Survival evaluation Safety and Tolerability evaluation	Gene mutations, serum markers and CTC analysis
7	Unknown ^†		Melanoma Stage III–IV			Treatment follow-up
8	Active, not recruiting	Molecular Characterization of Advanced Stage Melanoma by Blood Sampling	Metastatic Melanoma	CHU of Reims	Technological validation	ctDNA and CTC analysis
8	Active, not recruiting		Metastatic Melanoma	Reims, France	Survival evaluation
9	Recruiting	Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma	Metastatic Melanoma	University of Texas MD Anderson Cancer Center	Therapy and Survival evaluation	T cells and CTC analysis
9	Recruiting		Metastatic Melanoma	Houston, Texas, United States		Treatment follow-up
10	Completed	High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma	Metastatic Melanoma	Fuda Cancer Institute of Fuda Cancer Hospital	Therapy and Survival evaluation	Serum markers, lymphocytes and CTC analysis
10	Completed		Metastatic Melanoma	Guangzhou, Guangdong, China		Treatment follow-up
11	Unknown ^†	Circulating Melanoma Cells in Metastatic Patients Treated with Selective BRAF Inhibitors	Metastatic Melanoma	Istituto Oncologico Veneto IRCCS Padova, Italy	CTC evaluation during treatment	CTC Analysis
11	Unknown ^†		Metastatic Melanoma		Survival evaluation	Treatment follow-up

CHU: University hospital center, CTC: circulating tumor cell, ctDNA: circulating tumor DNA.